Abeona Therapeutics Joins Rare Disease Company Coalition
19 July 2023 - 10:30PM
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has
joined the Rare Disease Company Coalition (RDCC), an alliance of
life science companies committed to discovering, developing, and
delivering therapies for patients impacted by rare diseases.
Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., has
been appointed to the RDCC’s Board of Directors.
Mr. Seshadri said, "Abeona is thrilled to join
the RDCC and we share its passion and commitment for advancing rare
disease treatments for the patients we collectively serve. Given
Abeona’s focus on advancing EB-101 and providing durable wound
healing and pain reduction to patients with recessive dystrophic
epidermolysis bullosa, we understand the unique challenges and
opportunities that come with developing treatments for small and
differentiated patient populations. By working together with the
RDCC, we can advocate for policies and regulations that support
continued innovation and patient access to life-changing therapies.
We look forward to collaborating with our fellow coalition members
and contributing to the mission of improving the lives of millions
of people living with rare diseases."
About the Rare Disease Company Coalition
(RDCC) Founded in May 2021, the Rare Disease Company
Coalition represents life science companies committed to
discovering, developing and delivering rare disease treatments for
the patients we serve. As an education and advocacy-focused
coalition of companies, our goal is to inform policymakers of the
unique challenges and promises of rare disease drug discovery,
development and manufacturing for small population sizes so that
critical innovation can continue and positive changes can be
enacted for the rare disease community. To achieve this goal, we
will use our unified voice to advocate for long-term, consistent,
equitable and sustainable government policies that enable life
science companies to continue to bring hope and provide access to
approved treatments to people living with rare diseases. For more
information, please visit www.rarecoalition.com.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing cell and gene therapies for serious diseases.
Abeona’s lead clinical program is EB-101, its investigational
autologous, engineered cell therapy currently in development for
recessive dystrophic epidermolysis bullosa. The Company’s
development portfolio also features AAV-based gene therapies for
ophthalmic diseases with high unmet medical need. Abeona’s novel,
next-generation AAV capsids are being evaluated to improve tropism
profiles for a variety of devastating diseases. Abeona’s fully
integrated cell and gene therapy cGMP manufacturing facility
produces EB-101 for the pivotal Phase 3 VIITAL™ study and is
capable of clinical and potential commercial production of
AAV-based gene therapies. For more information, visit
www.abeonatherapeutics.com.
Forward-Looking Statements This
press release contains certain statements that are forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and that involve risks and uncertainties. We have
attempted to identify forward-looking statements by such
terminology as “may,” “will,” “believe,” “anticipate,” “expect,”
“intend,” and similar expressions (as well as other words or
expressions referencing future events, conditions or
circumstances), which constitute and are intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, numerous risks and uncertainties,
including but not limited to, the timing and outcome of our
Biologics License Application submission to the FDA for EB-101;
continued interest in our rare disease portfolio; our ability to
enroll patients in clinical trials; the outcome of future meetings
with the FDA or other regulatory agencies, including those relating
to preclinical programs; the ability to achieve or obtain necessary
regulatory approvals; the impact of any changes in the financial
markets and global economic conditions; risks associated with data
analysis and reporting; and other risks disclosed in the Company’s
most recent Annual Report on Form 10-K and subsequent periodic
reports filed with the Securities and Exchange Commission. The
Company undertakes no obligation to revise the forward-looking
statements or to update them to reflect events or circumstances
occurring after the date of this press release, whether as a result
of new information, future developments or otherwise, except as
required by the federal securities laws.
Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2024 to May 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From May 2023 to May 2024